- About About
Medical Patient Resources Cannabis Care Certification Patient's Guide to Medical Cannabis Patient's Guide to CBD Talking to your doctor Become a Legal Medical Marijuana Patient The Medical Cannabis Patient’s Guide for U.S. Travel Guide to Using Medical Cannabis Cannabis Tincture, Salve, Butter and Oil Recipes Arthritis and Medical Cannabis Cancer and Medical Cannabis Chronic Pain and Medical Cannabis Gastrointestinal Disorders and Medical Cannabis HIV/AIDS and Medical Cannabis Movement Disorders and Medical Cannabis Multiple Sclerosis and Medical Cannabis Aging and Medical Cannabis Veterans and Medical Cannabis Medical Marijuana Conditions in Your Area Growing Cannabis Tracking Treatment & Gathering Data with Releaf App Medical Professional Resources Medical Cannabis Continuing Medical Education (CME) Cannabis Safety Medical Cannabis Research
- Legal Legal
Advocacy ASA Chapters Start an ASA Chapter Take Action Campaigns No Patient Left Behind End Pain, Not Lives Vote Medical Marijuana Medical Cannabis Advocate's Training Center Resources for Tabling and Lobby Days Strategic Planning Civics 101 Strategic Messaging Citizen Lobbying Participating in Implementation Movement Building Organizing a Demonstration Organizing Turnout for Civic Meetings Public Speaking Media 101 Patient's History of Medical Cannabis
Policy Policy Positions Model Federal Legislation Download Ending The Federal Conflict Public Comments by ASA Industry Standards Guide to Regulating Industry Standards Recognizing Science using the Data Quality Act Data Quality Act Briefs Fact Sheet on ASA's Data Quality Act Petition to HHS ASA Data Quality Act petition to HHS Information on Lawyers and Named Patients in the Data Quality Act Lawsuit Reports 2021 State of the States Cannabis and Cannabis Resin- Critical Review Preparation Document Medical Cannabis in America
- News News
- Join Join
The ice bucket challenge has raised a huge amount of awareness for Amyotrophic Lateral Sclerosis (ALS) -- popularly known as Lou Gehrig's Disease. With the help of celebrities, politicians and thousands of participants from across the country, the ALS Association raised $94.3 million dollars for research. However, as awareness burgeons, many remain unaware of the significant benefits that medical marijuana has in treating ALS.
The endocannabinoid system helps us to “Eat, sleep, relax, forget, and protect.” This article is about how the endocannabinoid system can be stimulated to “protect” motor-neurons, the nerves (brain-type cells) that control body movement (Abood 2001).
Lou Gehrig’s disease (or ALS, Amyotrophic lateral sclerosis) is a fatal disease that affects degrades the neurons in the body that control movement. The hallmarks of ALS is a rapid progression of weakness and paralysis, death occurs within 3-5 years in most cases, and brain function remains intact (Rowland 2001) . The exact causes or pathogenesis of ALS is poorly understood, and while the pharmaceutical industry has made treatment options available, none of these treatments prevent disease progression and death.
The human clinical studies on THC-only Cannabis are limited by sample size. Research regulations for clinical use of THC also make it difficult to recruit ALS patients in a timely manner for a controlled study. Despite these significant obstacles, two human studies have been conducted. One of the studies, was a pilot study investigating the safety and tolerability of THC in ALS patients (Gelinas/ABood 2002). This clinical study confirmed symptomatic benefits for appetite, insomnia, and spasticity. The seconds research study was conducted as an anonymous survey in 80 countries, 131 surveys were completed, and the mean age 54. Participants reported that Cannabis helped provide relief from drooling, speech and swallowing difficulty, appetite loss, weakness, shortness of breath, spasticity, depression, and pain (Amtmann D 2004). In animals with ALS, THC administered either before or after the onset of the disease delayed motor impairment and prolonged survival. Furthermore, THC potently reduced oxidative and excite-toxic damage in spinal cord cultures in vitro (Raman et al. 2004). The protective effects of cannabinoids and their anti-spastic effects in MS are well known (Carter 2001). Furthermore, cannabinoid receptors are up-regulated in human tissue during disease progression, making them an abundant target for treatment.
The benefits of Cannabis to treat ALS is prevalent in anecdotal evidence, but basic laboratory and animal research suggests that THC may be the first (and only?) naturally occurring, non-toxic, anti-oxidant to slow the progressions of the disease significantly. In addition to delaying the progression of disease and increasing life-span cannabinoids treatments may offer other benefits include sleep induction, appetite stimulation, saliva reduction, bronchodilation, analgesia, and muscle relaxation (Carter).
Abood ME, Rizvi G, Sallapudi N, McAllister SD. 2001. Activation of the CB1 cannabinoid receptor protects cultured mouse spinal neurons against excitotoxicity. Neurosci Lett 309:197-201.
Amtmann D, Weydt P, Johnson KL, Jensen MP, Carter GT. 2004. Survey of cannabis use in patients with amyotrophic lateral sclerosis. Am J Hosp Palliat Care 21:95-104.
Carter GT, Rosen BS. 2001. Marijuana in the management of amyotrophic lateral sclerosis. Am J Hosp Palliat Care 18:264-70.
Gelinas DM, R; Abood, M. 2002. A pilot study of safety and tolerability of Delta 9-THC (Marinol) treatment for ALS. Amyotrophic lateral Sclerosis and Motor neuron Disorders 3.
Raman C, McAllister SD, Rizvi G, Patel SG, Moore DH, Abood ME. 2004. Amyotrophic lateral sclerosis: delayed disease progression in mice by treatment with a cannabinoid. Amyotroph Lateral Scler Other Motor Neuron Disord 5:33-9.
Rowland LP, Shneider NA. 2001. Amyotrophic lateral sclerosis. N Engl J Med 344:1688-700.